ArticleBlood advances2024
Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial.
Abstract read
In one paragraph
Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia.Blood cancer journal · 2026Article
- Long-Term Results of Busulfan Plus High-Dose Idarubicin as a Conditioning Regimen to Autologous Stem Cell Transplantation Following Cytarabine Consolidation in Young Patients with Favorable or Intermediate-Risk Acute Myeloid Leukemia.Blood and lymphatic cancer : targets and therapy · 2026Article
- Standardization of Measurable Residual Disease in Acute Myeloid Leukemia by Flow Cytometry: A Multicenter Study.EJHaem · 2025Article
- Article
- Article
- Stem cell transplantation indications for patients with acute leukemia determined by measurable residual disease: what we know and what we do not know.Blood science (Baltimore, Md.) · 2025Review
- Outcomes of acute myeloid leukemia with KMT2A (MLL) rearrangement: a multicenter study of TROPHY group.Blood cancer journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors.
Adriano VendittiHematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.ORCID 0000-0002-0245-0553
Alfonso PiciocchiGIMEMA Foundation, Rome, Italy.ORCID 0000-0001-8648-885X
Anna CandoniClinica Ematologica, Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine, Italy.
Valentina ArenaGIMEMA Foundation, Rome, Italy.ORCID 0000-0003-2782-2752
Raffaele PalmieriHematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.ORCID 0000-0003-2855-8121
Carla FilìClinica Ematologica, Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine, Italy.
Angelo Michele CarellaFondazione IRCCS Casa Sollievo della Sofferenza, UO di Ematologia, San Giovanni Rotondo, Italy.ORCID 0000-0002-4967-4204
Valeria CalafioreOspedale Ferrarotto, Catania, Italy.
Roberto CairoliASST Grande Ospedale Metropolitano Niguarda-Milano; Università degli Studi di Milano-Bicocca, Milan, Italy.
Paolo de FabritiisHematology, S.Eugenio Hospital, ASL Roma 2, University Tor Vergata, Rome, Italy.ORCID 0000-0002-1835-0581
Gabriella StortiAzienda Ospedaliera S. G. Moscati, Avellino, Italy.
Prassede SalutariAzienda USL di Pescara, Pescara, Italy.
Francesco LanzaEmatologia- Ospedale S. Maria delle Croci, Ravenna, Italy.
Giovanni MartinelliIRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori," Meldola, Italy.
Antonio CurtiIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli," Bologna, Italy.ORCID 0000-0002-7752-6049
Mario LuppiEmatologia, Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università degli Studi di Modena e Reggio Emilia, Modena, Italy.
Claudia IngrossoA. O. SS Annunziata-P. O. S. G. Moscati, Taranto, Italy.
Maria Paola MartelliOspedale S. Maria della Misericordia, Perugia, Italy.ORCID 0000-0001-9139-1729
Antonio CuneoAzienda Ospedaliero-Universitaria Arcispedale Sant'Anna, Ferrara, Italy.ORCID 0000-0003-2001-1308
Francesco AlbanoHematology and Stem Cell Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro," Bari, Italy.ORCID 0000-0001-7926-6052
Antonino MulèOspedali Riuniti Villa Sofia-Cervello, Palermo, Italy.ORCID 0009-0006-4162-2051
Agostino TafuriEmatologia, Azienda Ospedaliera Universitaria Sant' Andrea-Sapienza, Dipartimento di Medicina Clinica e Molecolare, Rome, Italy.
Laura CudilloUOC Ematologia, Azienda Ospedaliera S.Giovanni Addolorata, Rome, Italy.
Alessia TieghiS. C. Ematologia AUSL-IRCCS Reggio Emilia, Italy.
Nicola Stefano FracchiollaFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Debora CapelliAzienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.ORCID 0000-0002-9571-0579
Silvia Maria TrisoliniHaematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Caterina AlatiUOC Ematologia GOM Bianchi Melacrino Morelli, Reggio Calabria, Italy.
Edoardo La SalaGIMEMA Foundation, Rome, Italy.
Luca MaurilloFondazione Policlinico Tor Vergata, Rome, Italy.ORCID 0000-0001-7297-4988
Maria Ilaria Del PrincipeHematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.ORCID 0000-0002-3958-0669
Maria Antonietta Irno ConsalvoHematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
Maria Domenica DivonaFondazione Policlinico Tor Vergata, Rome, Italy.
Tiziana OttoneHematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.ORCID 0000-0003-1936-3592
Raffaella CerrettiFondazione Policlinico Tor Vergata, Rome, Italy.ORCID 0000-0003-3638-0650
Giuseppe SconocchiaInstitute of Translational Pharmacology, National Research Council, Rome, Italy.ORCID 0000-0003-3260-4856
Maria Teresa VosoHematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.ORCID 0000-0002-6164-4761
Paola FaziGIMEMA Foundation, Rome, Italy.
Marco VignettiGIMEMA Foundation, Rome, Italy.ORCID 0000-0003-1278-604X
Francesco BuccisanoHematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.ORCID 0000-0003-4320-9253
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Myeloid, AcuteNeoplasm, ResidualAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleTreatment OutcomeYoung Adult
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.